Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-05-16 00:00:00 ET · period of report 2024-05-14 · accession 0000875320-24-000144 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-16 | 2024-05-14 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | A - Grant | $0.00 | +14.1K | 30.1K | +88% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-14 | A | A | 14,112 | $0.00 | 30,084 | D | — | — | (F1) Represents earned performance shares with respect to a performance stock unit award granted on 05/19/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 05/14/2024 and the shares will vest on 06/10/2024. |